𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The case for iron chelation and/or antioxidant therapy in Alzheimer's disease

✍ Scribed by Elise A. Malecki; James R. Connor

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
70 KB
Volume
56
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Homocysteine-lowering therapy or antioxi
Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease
✍ Seung Hun Lee; Mi Jung Kim; Beom-Jun Kim; Sung Reul Kim; Sail Chun; Jin Sook Ryu πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 122 KB

## Abstract We investigated whether homocysteine (Hcy)‐ lowering therapy or an antioxidant prevented bone loss in Parkinson's disease (PD) patients taking levodopa. Forty‐two PD patients with low bone mineral density (BMD) taking levodopa were randomly assigned to Hcy‐lowering therapy (5 mg folate

The case for blood–brain barrier dysfunc
The case for blood–brain barrier dysfunction in the pathogenesis of Alzheimer's disease
✍ Brian Jeynes; John Provias πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 141 KB

## Abstract Alzheimer's disease (AD) is a neurodegenerative disease that leads to a progressive loss of integrative and memory capacities of the brain. This is the predominant form of neurodegenerative dementia, with a growing prevalence of between 1 in 50 and 1 in 100 in North America. Numerous hy